-
Je něco špatně v tomto záznamu ?
HIV resistance testing and detected drug resistance in Europe
A. Schultze, AN. Phillips, R. Paredes, M. Battegay, JK. Rockstroh, L. Machala, J. Tomazic, PM. Girard, I. Januskevica, K. Gronborg-Laut, JD. Lundgren, A. Cozzi-Lepri, . ,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Open Access Digital Library
od 1997-11-11
- MeSH
- dospělí MeSH
- genotyp MeSH
- HIV infekce farmakoterapie MeSH
- HIV-1 genetika MeSH
- inhibitory HIV-proteasy terapeutické užití MeSH
- inhibitory reverzní transkriptasy terapeutické užití MeSH
- kohortové studie MeSH
- látky proti HIV terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- logistické modely MeSH
- multivariační analýza MeSH
- neúspěšná terapie MeSH
- počet CD4 lymfocytů MeSH
- virová léková rezistence genetika MeSH
- virová nálož účinky léků MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
OBJECTIVES: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure. DESIGN: Multinational cohort study. METHODS: Individuals in EuroSIDA with virological failure (>1 RNA measurement >500 on ART after >6 months on ART) after 1997 were included. Adjusted odds ratios (aORs) for resistance testing following virological failure and aORs for the detection of resistance among those who had a test were calculated using logistic regression with generalized estimating equations. RESULTS: Compared to 74.2% of ART-experienced individuals in 1997, only 5.1% showed evidence of virological failure in 2012. The odds of resistance testing declined after 2004 (global P < 0.001). Resistance was detected in 77.9% of the tests, NRTI resistance being most common (70.3%), followed by NNRTI (51.6%) and protease inhibitor (46.1%) resistance. The odds of detecting resistance were lower in tests done in 1997-1998, 1999-2000 and 2009-2010, compared to those carried out in 2003-2004 (global P < 0.001). Resistance testing was less common in Eastern Europe [aOR 0.72, 95% confidence interval (CI) 0.55-0.94] compared to Southern Europe, whereas the detection of resistance given that a test was done was less common in Northern (aOR 0.29, 95% CI 0.21-0.39) and Central Eastern (aOR 0.47, 95% CI 0.29-0.76) Europe, compared to Southern Europe. CONCLUSIONS: Despite a concurrent decline in virological failure and testing, drug resistance was commonly detected. This suggests a selective approach to resistance testing. The regional differences identified indicate that policy aiming to minimize the emergence of resistance is of particular relevance in some European regions, notably in the countries in Eastern Europe.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010088
- 003
- CZ-PrNML
- 005
- 20160411125834.0
- 007
- ta
- 008
- 160408s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/QAD.0000000000000708 $2 doi
- 024 7_
- $a 10.1097/QAD.0000000000000708 $2 doi
- 035 __
- $a (PubMed)26091300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Schultze, Anna $u aDepartment of Infection and Population Health, University College London, London, UK bFundacions irsiCaixa i Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain cDivision of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Switzerland dUniversitäts Klinik, Bonn, Germany eDepartment of Infectious Diseases, Third Faculty of Medicine, Charles University and Hospital Na Bulovce in Prague, Czech Republic fClinic for Infectious Diseases, University Medical Centre, Ljubljana, Slovenia gService des Maladies Infectieuses, APHP, Hôpital St Antoine and INSERM, UMR_S1136, Paris, France hState Agency Infectology Center of Latvia, Riga, Latvia iRigshospitalet, University of Copenhagen, CHIP at Department of Infectious Diseases, Copenhagen, Denmark.
- 245 10
- $a HIV resistance testing and detected drug resistance in Europe / $c A. Schultze, AN. Phillips, R. Paredes, M. Battegay, JK. Rockstroh, L. Machala, J. Tomazic, PM. Girard, I. Januskevica, K. Gronborg-Laut, JD. Lundgren, A. Cozzi-Lepri, . ,
- 520 9_
- $a OBJECTIVES: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure. DESIGN: Multinational cohort study. METHODS: Individuals in EuroSIDA with virological failure (>1 RNA measurement >500 on ART after >6 months on ART) after 1997 were included. Adjusted odds ratios (aORs) for resistance testing following virological failure and aORs for the detection of resistance among those who had a test were calculated using logistic regression with generalized estimating equations. RESULTS: Compared to 74.2% of ART-experienced individuals in 1997, only 5.1% showed evidence of virological failure in 2012. The odds of resistance testing declined after 2004 (global P < 0.001). Resistance was detected in 77.9% of the tests, NRTI resistance being most common (70.3%), followed by NNRTI (51.6%) and protease inhibitor (46.1%) resistance. The odds of detecting resistance were lower in tests done in 1997-1998, 1999-2000 and 2009-2010, compared to those carried out in 2003-2004 (global P < 0.001). Resistance testing was less common in Eastern Europe [aOR 0.72, 95% confidence interval (CI) 0.55-0.94] compared to Southern Europe, whereas the detection of resistance given that a test was done was less common in Northern (aOR 0.29, 95% CI 0.21-0.39) and Central Eastern (aOR 0.47, 95% CI 0.29-0.76) Europe, compared to Southern Europe. CONCLUSIONS: Despite a concurrent decline in virological failure and testing, drug resistance was commonly detected. This suggests a selective approach to resistance testing. The regional differences identified indicate that policy aiming to minimize the emergence of resistance is of particular relevance in some European regions, notably in the countries in Eastern Europe.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a látky proti HIV $x terapeutické užití $7 D019380
- 650 _2
- $a počet CD4 lymfocytů $7 D018791
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a virová léková rezistence $x genetika $7 D024882
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a HIV infekce $x farmakoterapie $7 D015658
- 650 _2
- $a inhibitory HIV-proteasy $x terapeutické užití $7 D017320
- 650 _2
- $a HIV-1 $x genetika $7 D015497
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a inhibitory reverzní transkriptasy $x terapeutické užití $7 D018894
- 650 _2
- $a neúspěšná terapie $7 D017211
- 650 _2
- $a virová nálož $x účinky léků $7 D019562
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Phillips, Andrew N
- 700 1_
- $a Paredes, Roger
- 700 1_
- $a Battegay, Manuel
- 700 1_
- $a Rockstroh, Jürgen K
- 700 1_
- $a Machala, Ladislav
- 700 1_
- $a Tomazic, Janez
- 700 1_
- $a Girard, Pierre M
- 700 1_
- $a Januskevica, Inga
- 700 1_
- $a Gronborg-Laut, Kamilla
- 700 1_
- $a Lundgren, Jens D
- 700 1_
- $a Cozzi-Lepri, Alessandro
- 700 1_
- $a ,
- 773 0_
- $w MED00000179 $t AIDS (London, England) $x 1473-5571 $g Roč. 29, č. 11 (2015), s. 1379-89
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26091300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160411125916 $b ABA008
- 999 __
- $a ok $b bmc $g 1113517 $s 934456
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 29 $c 11 $d 1379-89 $i 1473-5571 $m AIDS $n AIDS $x MED00000179
- LZP __
- $a Pubmed-20160408